SAGE Therapeutics

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SAGE Therapeutics poised for Zuranolone launch in 2023, overcoming challenges

SAGE Therapeutics showcased strong financial performance and promising developments with Zuranolone, positioning the drug favorably for potential launch in 2023.
While facing challenges such as enrollment issues and DEA scheduling impacts, the company is leveraging opportunities in commercialization strategies and post-marketing studies to enhance Zuranolone's market presence.
Overall, Zuranolone's rapid and durable effects, alignment with current treatment practices, and targeted commercialization approach present a compelling opportunity for SAGE Therapeutics in the mental health treatment landscape.
By addressing challenges effectively and capitalizing on opportunities, SAGE Therapeutics is poised to make a significant impact in advancing treatments for mood disorders and improving patient outcomes.

Sage Therapeutics reports strong Q1 performance and eyes market expansion

Sage Therapeutics had a strong Q1 2023, focusing on brain health medicines and preparing for zuranolone's launch.
The company's financial position is solid, with growth opportunities in pipeline programs and proactive payer engagements.
Challenges include regulatory uncertainties and competition, but Sage is well-positioned to capitalize on market demand.
Opportunities lie in expanding product indications, proactive agreements with payers, and learning from competitors for strategic advantage.

SAGE Therapeutics to Launch Zurzuvae for Postpartum Depression, Overcomes FDA Setback

SAGE Therapeutics is poised to launch Zurzuvae for postpartum depression, leveraging its financial strength and clinical success. While facing challenges in MDD, the company is strategically adapting to focus on PPD and enhance operational efficiency. Opportunities lie in collaborations, pricing strategies, and addressing the significant market need for PPD treatments.

SAGE Therapeutics advances women's health with ZURZUVAE approval

SAGE Therapeutics navigates financial challenges while advancing innovative treatments for women's health.
ZURZUVAE's approval and commercialization plans present opportunities in a significant market segment.
Strategic focus on engagement, access, and market positioning key to ZURZUVAE's success.
Pipeline advancements and collaboration efforts position SAGE for future growth and impact.

SAGE Therapeutics excels with ZURZUVAE launch, poised for continued growth

SAGE Therapeutics had a strong performance in 2023, driven by the successful launch of ZURZUVAE and positive early market reception.
While facing challenges in data tracking and market competition, the company's focus on innovation and patient access presents growth opportunities.
With a robust pipeline and strategic initiatives in place, SAGE is well-positioned to maintain momentum and drive further success in the brain health space.

SAGE Therapeutics reports strong Zurzuvae launch amidst Parkinson's study setback

SAGE Therapeutics is navigating challenges from the PRECEDENT study while capitalizing on Zurzuvae's successful launch for PPD.
The company's pipeline progress and commitment to addressing cognitive disorders in neurodegenerative diseases showcase a strong focus on brain health.
Collaborative efforts with Biogen, strong payer coverage, and positive market feedback position Zurzuvae as a frontline treatment for PPD.
Strategic initiatives to educate prescribers, expand market reach, and refine study designs present promising growth opportunities for SAGE.

SAGE Therapeutics faces setbacks but sees success with ZURZUVAE in Q2

SAGE Therapeutics navigates setbacks with SAGE-324 study closure but sees success with ZURZUVAE in PPD treatment. Strong financial foundation and commitment to brain health initiatives position the company for future growth.

SAGE Therapeutics focuses on Zurzuvae for PPD treatment success

SAGE Therapeutics prioritizes Zurzuvae for PPD, showing strong revenue growth and prescription uptake
Challenges include discontinuation of certain programs and mixed results in clinical studies
Opportunities lie in focusing resources, upcoming study results, and strategic program ownership
Overall, SAGE's reorganization reflects a strategic shift towards maximizing Zurzuvae's potential

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

At Home Group

Elastic N.V

Some bad news sent several stocks sharply lower.

Why At Home Group, Elastic, and Sage Therapeutics Slumped Today

Sage Therapeutics (NASDAQ:SAGE) is in the news Thursday as SAGE stock takes a dive following depressing results from a study. 
The post Sage Therapeutics News: SAGE Stock Dives 60% on Depression Study Failure appeared first on InvestorPlace.

Sage Therapeutics News: SAGE Stock Dives 60% on Depression Study Failure

An important clinical trial turned in underwhelming results.

Here's Why Sage Therapeutics Lost as Much as 62.1% Today

ACADIA Pharma

Aurinia Pharmaceuticals

Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff.

Thursday’s Biggest Biotech Movers

Shares of thinly-traded, mid-cap biotech SAGE Therapeutics Inc NASDAQ: SAGE) are melting down after the company flunked in a late-stage trial of its lead CNS disorder drug candidate SAGE-217 in major depressive disorder, or MDD.

Sage Therapeutics Shares Toppled By Failed Mountain Study Of Depression Drug

Shares of Sage Therapeutics collapsed Thursday after the biotech company's depression treatment, dubbed SAGE-217, failed to meet its key goal at day 15 in a late-stage study.

This Biotech Collapsed 60% After Its Depression Drug Unexpectedly Failed

Shares of Sage Therapeutics Inc. SAGE, -0.38% were indicated down nearly 9% in premarket trading Thursday, after the biopharmaceutical company said a Phase 3 study of its SAGE-217 for the treatment of major depressive disorder failed to meet the primary endpoint.

Sage Therapeutics's stock set for selloff after depression treatment study fails primary endpoint

Sage Therapeutics, Inc. (SAGE) CEO Jeff Jonas on Q3 2019 Results - Earnings Call Transcript

AC Immune

Ascendis Pharma

Eyenovia

Ngm Biopharmaceuticals Inc

Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.

5 Biotech Stocks Set to Beat Q3 Earnings Estimates

Sage Therapeutics is engaged in developing and commercialising novel medicines to treat life-altering central nervous system disorders.

Sage Therapeutics Looks A Buy At Current Price

SAGE-217 is likely to see Phase 3 trial success due to a well understood mechanism of action and superb Phase 2 clinical data.

Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation

Sage Therapeutics could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Moving Average Crossover Alert: Sage Therapeutics

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q2 2019 Results Conference Call August 6, 2019 8:00 AM ET

Sage Therapeutics, Inc. (SAGE) CEO Dr. Jeff Jonas on Q2 2019 Results - Earnings Call Transcript

Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Sage Therapeutics (SAGE) Q2 Earnings Expected to Decline

"We feel we should be able to price it for the value it'll provide for patients," Sage Therapeutics CEO Jeff Jonas tells CNBC.

Sage Therapeutics should price experimental depression pill on 'value' despite politics, CEO says

Zulresso injectable is targeting a highly underserved market segment.

Sage Therapeutics: A Promising CNS Play In July 2019

Sage Therapeutics Inc (SAGE) President & CEO Jeffrey M Jonas Sold $15 million of Shares

Sage Therapeutics' (SAGE) CEO Jeff Jonas on Q1 2019 Results - Earnings Call Transcript

In June, Sage Therapeutics’ postpartum depression drug Zulresso, the first and only medicine approved by the FDA to specifically treat the condition, will hit the market.

Sage Therapeutics’ Zulresso is a big win for postpartum depression sufferers — and maybe even the entire mental health community

Sage shot higher in January off of encouraging clinical data and Zulresso approval.

Sage Is Still Undervalued Even After Recent Spike

A midsize acquisition seems imminent, and these two would fit like a glove.

2 Biotech Takeout Targets Perfect for Biogen: Sage Therapeutics

Sage Therapeutics stock jumped Wednesday after the FDA approved its postpartum depression treatment, Zulresso. Investors are now looking at another depression drug called SAGE-217.

This Biotech Stock Grabbed A First In Depression — So What's Next?

Shares of mid-cap biotech SAGE Therapeutics Inc, which focuses on therapies for central nervous system disorders, were trading higher Wednesday.

Sage's First-Of-Its-Kind Postpartum Depression Drug Clears FDA Hurdle: What You Need to Know

Shares of Sage Therapeutics jumped after hours Tuesday based on news that the FDA approved the first postpartum depression drug called Zulresso.

FDA approves first postpartum depression treatment Zulresso -- Sage stock jumps after hours

Amarin Corporation Plc

AstraZeneca

Jazz Pharmaceuticals

Ligand Pharmaceuticals

Leap Therapeutics

Lexicon Pharmaceuticals

PhaseBio Pharmaceuticals Inc

Roche Holding AG

Strongbridge Biopharma

Sanofi

Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support.

News for SAGE Therapeutics Stock (SAGE)